MWNA
KRRO icon

Marshall Wace North America’s Korro Bio KRRO Stock Holding History

Marshall Wace North America’s Portfolio KRRO Stock Details KRRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-123
Closed -$217K – 1644
2020
Q4 		$217K Buy
+123
New +$162K ﹤0.01% 1217
2020
Q2 		– Sell
-104
Closed -$93K – 1320
2020
Q1 		$93K Sell
104
-192
-65% -$207K ﹤0.01% 1004
2019
Q4 		$259K Buy
+296
New +$230K ﹤0.01% 922

Other funds holding KRRO

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Marshall Wace North America's KRRO Position: Q1 2021 in Review

Marshall Wace North America sold out of Korro Bio (KRRO) in Q1 2021, closing a stake of 123 shares — an estimated $217K sold.

Marshall Wace North America first reported a position in KRRO in Q4 2019 and held it in 3 quarters. The position peaked at $259K in Q4 2019. 115 funds tracked by Wall St. Rank hold KRRO as of Q1 2021.

  • Marshall Wace North America reported no remaining Korro Bio position as of Q1 2021 after selling out during the quarter.
  • Marshall Wace North America sold 123 Korro Bio shares in Q1 2021, an estimated $217K.
  • Marshall Wace North America first reported a position in Korro Bio in Q4 2019 and held it in 3 quarters.
  • Marshall Wace North America's Korro Bio position peaked at $259K in Q4 2019.
  • 115 funds tracked by Wall St. Rank held Korro Bio as of Q1 2021.

Based on Marshall Wace North America's 13F filing for Q1 2021, filed 17 May 2021.